Clinical effectiveness and cost-effectiveness of foot orthoses for people with established rheumatoid arthritis: an exploratory clinical trial

被引:25
|
作者
Rome, K. [1 ]
Clark, H. [2 ]
Gray, J. [3 ]
McMeekin, P. [3 ]
Plant, M. [4 ]
Dixon, J. [5 ]
机构
[1] AUT Univ, Rehabil & Res Inst, Sch Podiatry, Auckland 0627, New Zealand
[2] South Tees Hosp NHS Fdn Trust, Podiatry Dept, Middlesbrough, Cleveland, England
[3] Northumbria Univ, Dept Publ Hlth & Wellbeing, Newcastle Upon Tyne, Tyne & Wear, England
[4] South Tees Hosp NHS Fdn Trust, Dept Rheumatol, Middlesbrough, Cleveland, England
[5] Teesside Univ, Hlth & Social Care Inst, Middlesbrough, Cleveland, England
关键词
PAIN; DISABILITY; DISEASE;
D O I
10.1080/03009742.2016.1196500
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Foot orthoses are commonly prescribed as an intervention for people with rheumatoid arthritis (RA). Data relating to the cost-effectiveness of foot orthoses in people with RA are limited. The aim was to evaluate the clinical and cost-effectiveness of two types of foot orthoses in people with established RA.Method: A single-blind randomized controlled trial was undertaken to compare custom-made foot orthoses (CMFOs) and simple insoles (SIs) in 41 people with established RA. The Foot Function Index (FFI) was used to measure foot pain, disability, and functional limitation. Costs were estimated from the perspective of the UK National Health Service (NHS), societal (patient and family) perspective, and secondary care resource use in terms of the intervention and staff time. Effects were assessed in terms of health gain expressed as quality-adjusted life years (QALYs).Results: At baseline, 20 participants received a CMFO and 21 participants received an SI. After 16weeks foot pain improved in both the CMFOs (p=0.000) and the SIs (p<0.01). However, disability scores improved for CMFOs (p<0.001) but not for SIs (p=0.40). The cost-effectiveness results demonstrated no difference in cost between the arms (CMFOs: 159.10; SIs: 79.10; pound p=0.35), with the CMFOs being less effective in terms of cost per QALY gain (p<0.001).Conclusions: In people with established RA, semi-rigid customized foot orthoses can improve pain and disability scores in comparison to simple insoles. From a cost-effectiveness perspective, the customized foot orthoses were far more expensive to manufacture, with no significant cost per QALY gain.
引用
收藏
页码:187 / 193
页数:7
相关论文
共 50 条
  • [31] Clinical effectiveness and cost-effectiveness of a multifaceted podiatry intervention for falls prevention in older people: a multicentre cohort randomised controlled trial (the REducing Falls with ORthoses and a Multifaceted podiatry intervention trial)
    Cockayne, Sarah
    Rodgers, Sara
    Green, Lorraine
    Fairhurst, Caroline
    Adamson, Joy
    Scantlebury, Arabella
    Corbacho, Belen
    Hewitt, Catherine E.
    Hicks, Kate
    Hull, Robin
    Keenan, Anne-Maree
    Lamb, Sarah E.
    McIntosh, Caroline
    Menz, Hylton B.
    Redmond, Anthony
    Richardson, Zoe
    Vernon, Wesley
    Watson, Judith
    Torgerson, David J.
    HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (24) : 1 - +
  • [32] Clinical effectiveness and cost-effectiveness of nurse-led care in Chinese patients with rheumatoid arthritis: A randomized trial comparing with rheumatologist-led care
    Wang, Junru
    Zou, Xiulan
    Cong, Ling
    Liu, Huina
    INTERNATIONAL JOURNAL OF NURSING PRACTICE, 2018, 24 (01)
  • [33] Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy
    Gaultney, J.
    Benucci, M.
    Iannazzo, S.
    Nappi, C.
    Sion, K.
    Sabater, F. J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (03) : 409 - 417
  • [34] THE COST-EFFECTIVENESS OF ALTERNATIVE TREATMENT SEQUENCES IN RHEUMATOID ARTHRITIS
    Trueman, D.
    Bird, A.
    Mumby-Croft, J.
    VALUE IN HEALTH, 2014, 17 (03) : A48 - A48
  • [35] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [36] Cost-effectiveness of lifelong infliximab for rheumatoid arthritis in Portugal
    Wong, JB
    Branco, JC
    Cobrado, N
    Nero, P
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 360 - 360
  • [37] COST-EFFECTIVENESS OF ABATACEPT OR INFLIXIMAB IN RHEUMATOID ARTHRITIS IN COLOMBIA
    Alfonso-Cristancho, R.
    Aiello, E. C.
    Roa, C. N.
    VALUE IN HEALTH, 2011, 14 (03) : A127 - A127
  • [38] Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis
    Ruchlin, HS
    Elkin, EB
    Paget, SA
    ARTHRITIS CARE & RESEARCH, 1997, 10 (06) : 413 - 421
  • [39] COST-EFFECTIVENESS OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CHINA
    Wang, B. C.
    Chen, Y.
    Furnback, W.
    Wu, Q.
    Dong, P.
    VALUE IN HEALTH, 2018, 21 : S197 - S197
  • [40] Cost-Effectiveness of Biologics in Early Rheumatoid Arthritis RESPONSE
    Boers, Maarten
    ANNALS OF INTERNAL MEDICINE, 2010, 152 (05) : 334 - 334